← Back to patent-cliff list
E2086
Tier C — Watch / tradeE2086
Eisai Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Orexin receptor
Indications (approved)：发作性睡病
Regional status
US
Phase II
2026-03-26
EU
Phase II
2026-03-26
China
Phase II
2026-03-26
Japan
Phase II
2026-03-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of E2086?
Approved indications include: 发作性睡病.
When does the E2086 patent expire?
No public expiry year is available for E2086 yet; this page updates once verified.
How do I get a quote for E2086 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29